Literature DB >> 24052549

Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies.

Deepa Manwani1, Paul S Frenette.   

Abstract

Recurrent and unpredictable episodes of vaso-occlusion are the hallmark of sickle cell disease. Symptomatic management and prevention of these events using the fetal hemoglobin-reactivating agent hydroxyurea are currently the mainstay of treatment. Discoveries over the past 2 decades have highlighted the important contributions of various cellular and soluble participants in the vaso-occlusive cascade. The role of these elements and the opportunities for therapeutic intervention are summarized in this review.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24052549      PMCID： PMC3854110          DOI： 10.1182/blood-2013-05-498311

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  54 in total

1.  Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease.

Authors:  Diana R Gutsaeva; James B Parkerson; Shobha D Yerigenahally; Jeffrey C Kurz; Robert G Schaub; Tohru Ikuta; C Alvin Head
Journal:  Blood       Date:  2010-10-06       Impact factor: 22.113

2.  Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.

Authors:  Donald Lavelle; Kestis Vaitkus; Yonghua Ling; Maria A Ruiz; Reda Mahfouz; Kwok Peng Ng; Soledad Negrotto; Nicola Smith; Pramod Terse; Kory J Engelke; Joseph Covey; Kenneth K Chan; Joseph Desimone; Yogen Saunthararajah
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

3.  GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice.

Authors:  Jungshan Chang; John T Patton; Arun Sarkar; Beat Ernst; John L Magnani; Paul S Frenette
Journal:  Blood       Date:  2010-05-27       Impact factor: 22.113

Review 4.  The molecular pathobiology of cell membrane iron: the sickle red cell as a model.

Authors:  P Browne; O Shalev; R P Hebbel
Journal:  Free Radic Biol Med       Date:  1998-04       Impact factor: 7.376

5.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

Authors:  A Samuelsson; T L Towers; J V Ravetch
Journal:  Science       Date:  2001-01-19       Impact factor: 47.728

Review 6.  A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease.

Authors:  Abdullah Kutlar; Kenneth I Ataga; Lillian McMahon; Joanna Howard; Frederic Galacteros; Ward Hagar; Elliott Vichinsky; Anthony T W Cheung; Neil Matsui; Stephen H Embury
Journal:  Am J Hematol       Date:  2012-04-10       Impact factor: 10.047

7.  Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson.

Authors:  Joshua J Field; Gene Lin; Maureen M Okam; Elaine Majerus; Jeffrey Keefer; Onyinye Onyekwere; Ainsley Ross; Federico Campigotto; Donna Neuberg; Joel Linden; David G Nathan
Journal:  Blood       Date:  2013-02-01       Impact factor: 22.113

8.  Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice.

Authors:  Camila Bononi Almeida; Christoph Scheiermann; Jung-Eun Jang; Colette Prophete; Fernando Ferreira Costa; Nicola Conran; Paul S Frenette
Journal:  Blood       Date:  2012-07-25       Impact factor: 22.113

Review 9.  Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins.

Authors:  Dominik J Schaer; Paul W Buehler; Abdu I Alayash; John D Belcher; Gregory M Vercellotti
Journal:  Blood       Date:  2012-12-20       Impact factor: 22.113

10.  Platelet activation and inhibition in sickle cell disease (pains) study.

Authors:  Andrew L Frelinger; Joseph A Jakubowski; Julie K Brooks; Sabrina L Carmichael; Michelle A Berny-Lang; Marc R Barnard; Matthew M Heeney; Alan D Michelson
Journal:  Platelets       Date:  2013-03-07       Impact factor: 3.862
View more
  116 in total

Review 1.  Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology.

Authors:  Dachuan Zhang; Chunliang Xu; Deepa Manwani; Paul S Frenette
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

Review 2.  Neuronal transient receptor potential (TRP) channels and noxious sensory detection in sickle cell disease.

Authors:  Katelyn E Sadler; Cheryl L Stucky
Journal:  Neurosci Lett       Date:  2018-11-30       Impact factor: 3.046

3.  Resolution of sickle cell disease-associated inflammation and tissue damage with 17R-resolvin D1.

Authors:  Alessandro Matte; Antonio Recchiuti; Enrica Federti; Bérengère Koehl; Thomas Mintz; Wassim El Nemer; Pierre-Louis Tharaux; Valentine Brousse; Immacolata Andolfo; Alessia Lamolinara; Olga Weinberg; Angela Siciliano; Paul C Norris; Ian R Riley; Achille Iolascon; Charles N Serhan; Carlo Brugnara; Lucia De Franceschi
Journal:  Blood       Date:  2018-11-07       Impact factor: 22.113

4.  Red blood cells and thrombin generation in sickle cell disease.

Authors:  Matthew F Whelihan; Ming Y Lim; Nigel S Key
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

5.  Quantitative microfluidic fluorescence microscopy to study vaso-occlusion in sickle cell disease.

Authors:  Maritza A Jimenez; Egemen Tutuncuoglu; Suchitra Barge; Enrico M Novelli; Prithu Sundd
Journal:  Haematologica       Date:  2015-05-14       Impact factor: 9.941

6.  [Hemoglobin disorders].

Authors:  R Dickerhoff
Journal:  Internist (Berl)       Date:  2015-09       Impact factor: 0.743

7.  Drug development: a complicated path.

Authors:  Courtney Humphries
Journal:  Nature       Date:  2014-11-13       Impact factor: 49.962

8.  Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use.

Authors:  Marilyn J Telen; Ted Wun; Timothy L McCavit; Laura M De Castro; Lakshmanan Krishnamurti; Sophie Lanzkron; Lewis L Hsu; Wally R Smith; Seungshin Rhee; John L Magnani; Helen Thackray
Journal:  Blood       Date:  2015-03-02       Impact factor: 22.113

Review 9.  Regulation of leucocyte homeostasis in the circulation.

Authors:  Christoph Scheiermann; Paul S Frenette; Andrés Hidalgo
Journal:  Cardiovasc Res       Date:  2015-03-05       Impact factor: 10.787

10.  Pain Intensity Assessment in Sickle Cell Disease Patients Using Vital Signs During Hospital Visits.

Authors:  Swati Padhee; Amanuel Alambo; Tanvi Banerjee; Arvind Subramaniam; Daniel M Abrams; Gary K Nave; Nirmish Shah
Journal:  Pattern Recognit (2021)       Date:  2021-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.